Gettinger S, et al. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. Abstract OA14.04. WCLC 7-10 sept. 2019, Barcelona, Spanje.
Durvalumab na chemoradiotherapie bij stadium III niet-kleincellig longcarcinoom
aug 2018 | Longoncologie